AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

BioXcel Therapeutics Inc. (BTAI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.85

0.21 (7.95%)

At close: Feb 10, 2025, 11:46 AM

undefined% (undefined)

Bid	2.83
Market Cap	8.48M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-32.64
PE Ratio (ttm)	-0.09
Forward PE	n/a
Analyst	Buy

Ask	2.87
Volume	245,595
Avg. Volume (20D)	118,620
Open	2.89
Previous Close	2.64
Day's Range	2.74 - 3.15
52-Week Range	2.56 - 61.12
Beta	undefined

About BTAI

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 8, 2018

Employees 74

Stock Exchange NASDAQ

Ticker Symbol BTAI

Website https://www.bioxceltherapeutics.com

Analyst Forecast

According to 4 analyst ratings, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 1023.44% from the latest price.

Buy 50.00%

Hold 25.00%

Sell 25.00%

Stock Forecasts

Next Earnings Release

BioXcel Therapeutics Inc. is scheduled to release its earnings on Mar 11, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 days ago

-37.57%

BioXcel Therapeutics shares are trading lower afte... Unlock content with Pro Subscription

1 month ago

-17.78%

BioXcel Therapeutics shares are trading lower after B of A Securities downgraded the stock from Buy to Underperform and cut its price target from $7 to $0.25.

News

1 month ago · zacks.com

BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · zacks.com

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 per share a year ago.

2 months ago · seekingalpha.com

BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript

BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer Richard Steinhart - Chief Financial O...